$RMTI: ROCKWELL MEDICAL, INC. FILES PRE-IND MEETIN
Post# of 144494
(Total Views: 67)
Posted On: 07/28/2021 11:03:33 AM
$RMTI: ROCKWELL MEDICAL, INC. FILES PRE-IND MEETING REQUEST WITH FDA FOR ITS PROPOSED CLINICAL TRIAL OF FPC AS A TREATMENT FOR IRON DEFICIENCY ANEMIA IN PATIENTS RECEIVING HOME INFUSION
Click here:
https://www.globenewswire.com/news-release/20...usion.html
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.
For more information, visit www.RockwellMed.com.
Click here:
https://www.globenewswire.com/news-release/20...usion.html
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients' lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.
For more information, visit www.RockwellMed.com.
(0)
(0)Scroll down for more posts ▼